The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested target is correctly identified: human USH1C encodes harmonin, UniProt Q9Y6N9, also called the Usher syndrome type-1C protein. The literature consistently uses USH1C/harmonin for this human protein; no conflicting same-symbol protein was encountered. USH1C lies on chromosome 11, contains 28 exons across more than 50 kb, and has at least 11 annotated human transcripts. Its extensive alternative splicing generates the major harmonin a, b and c isoform groups. The domains specified in the supplied UniProt record—an N-terminal harmonin/HHD module and multiple PDZ domains—agree with structural and functional studies. (yu2017myosin7and pages 3-3, nagelwolfrum2023expressionandsubcellular pages 1-2, leith2025currentapproachesfor pages 2-3)
Harmonin is not an enzyme, transporter, receptor, or ion channel. Its primary function is that of a multivalent cytoplasmic scaffold/adaptor: it recognizes membrane-protein tails through PDZ domains, recruits SANS/ANKS4B and myosin-VII motors, and couples cadherin-based adhesion or tip-link complexes to cortical F-actin. Its best-established physiological role is at the upper insertion of hair-cell stereociliary tip links, where it organizes and mechanically anchors part of the mechanoelectrical-transduction apparatus. It also organizes related adhesion/cytoskeletal assemblies in retinal photoreceptors, Müller glia and intestinal brush-border microvilli. (yu2017myosin7and pages 3-3, whatley2020ushersyndromegenetics pages 12-13, dinculescu2021retinalgenetherapy pages 4-6)
| Aspect | Best-supported annotation | Evidence type | Key source/date/DOI URL |
|---|---|---|---|
| Identity | UniProt Q9Y6N9 is the human USH1C gene product harmonin (Usher syndrome type-1C protein), a nonenzymatic scaffold/adaptor; the supplied accession and organism match the literature target. | Human gene annotation, expression studies, and biochemical interaction evidence | Nagel-Wolfrum et al., Jan. 2023, 10.1093/hmg/ddac211; Reiners et al., 21 Nov. 2005, 10.1093/hmg/ddi417 (reiners2005scaffoldproteinharmonin pages 1-2, nagelwolfrum2023expressionandsubcellular pages 1-2) |
| Domains and isoforms | Alternative splicing produces harmonin a, b, and c groups. Shared architecture includes an N-terminal harmonin/HHD region, PDZ1–PDZ2, and coiled-coil elements; a/b contain PDZ3, while the longer b forms add coiled-coil/PST actin-binding elements. PDZ domains recognize partner PDZ-binding motifs. | Transcript annotation, biochemistry, and high-resolution structural analysis | Yu et al., June 2017, 10.1038/ncomms15864; Nagel-Wolfrum et al., Jan. 2023, 10.1093/hmg/ddac211 (yu2017myosin7and pages 3-3, nagelwolfrum2023expressionandsubcellular pages 1-2, leith2025currentapproachesfor pages 2-3) |
| Cochlear upper tip-link role | Harmonin-b concentrates at the stereociliary upper tip-link density, where it scaffolds CDH23, SANS and MYO7A and couples the membrane tip-link apparatus to F-actin. Loss or disruption alters hair-bundle morphogenesis and mechanoelectrical-transduction adaptation; harmonin is an anchor/regulator, not the ion channel itself. | Localization, mutant electrophysiology, binding assays, and complex structures | Whatley et al., Oct. 2020, 10.3389/fgene.2020.565216; Yu et al., June 2017, 10.1038/ncomms15864 (yu2017myosin7and pages 3-3, whatley2020ushersyndromegenetics pages 12-13, leith2025currentapproachesfor pages 2-3) |
| Human retinal localization | Human retinal RNA-seq identified harmonin_a1 as the most abundant USH1C transcript. Protein was detected in rod outer segments, cone presynaptic pedicles, Müller-glial endfeet and apical microvilli, and Müller-glia–photoreceptor adhesive junctions at the outer limiting membrane; interaction with rhodopsin was supported experimentally, whereas a PDZ2-binding model remains predictive. | Human RNA-seq, immunoblotting, immunofluorescence/electron microscopy, proximity-ligation and pull-down assays | Nagel-Wolfrum et al., Jan. 2023, 10.1093/hmg/ddac211 (nagelwolfrum2023expressionandsubcellular pages 8-11, nagelwolfrum2023expressionandsubcellular pages 1-2) |
| Intestinal brush border | Harmonin participates in the epithelial intermicrovillar adhesion complex, binding CDHR2/CDHR5 tails and assembling with MYO7B and ANKS4B to connect cadherin adhesion complexes to actin and organize brush-border microvilli. This is a structural role rather than catalysis or transport. | Biochemical interaction assays, structural biology, and epithelial-cell organization studies | Yu et al., June 2017, 10.1038/ncomms15864 (yu2017myosin7and pages 3-3, dinculescu2021retinalgenetherapy pages 4-6) |
| Disease mechanism | Biallelic loss-of-function or disruptive USH1C variants destabilize sensory adhesion–cytoskeleton assemblies, impair stereociliary development/MET and disrupt retinal architecture or ciliary organization, causing autosomal-recessive USH1C with congenital severe-to-profound hearing loss, vestibular dysfunction and progressive retinal degeneration. Retinal mechanisms likely involve both photoreceptors and Müller glia. | Human genetics and phenotype, mutant animals, patient cells, and human retinal localization | Nagel-Wolfrum et al., Jan. 2023, 10.1093/hmg/ddac211; Dinculescu et al., Sept. 2021, 10.1097/IIO.0000000000000378 (nagelwolfrum2023expressionandsubcellular pages 8-11, nagelwolfrum2023expressionandsubcellular pages 1-2, dinculescu2021retinalgenetherapy pages 4-6) |
| ASO, AAV and editing status | For the Acadian c.216G>A cryptic-splice variant, ASOs corrected splicing and rescued auditory/vestibular phenotypes most effectively after early treatment in mice; neonatal AAV delivery produced low-frequency auditory rescue. ZFN correction and other editing/replacement approaches remain cell- or animal-model work. These results are promising but mutation-, delivery- and developmental-window dependent. | Preclinical mouse, cell, and review evidence; no demonstrated human efficacy | Cuzzuol et al., Jan. 2024, 10.5319/wjo.v11.i1.1; Whatley et al., Oct. 2020, 10.3389/fgene.2020.565216 (cuzzuol2024ushersyndromegenetic pages 5-6, toms2020ushersyndromeclinical pages 8-10, leith2025currentapproachesfor pages 21-22, whatley2020ushersyndromegenetics pages 15-16) |
| Clinical status and epidemiology | No USH1C-specific interventional clinical trial was identified in the searched evidence; current care uses hearing rehabilitation/cochlear implantation and surveillance/support for retinal disease. Published prevalence values such as approximately 1 in 29,000 apply to all Usher subtypes and must not be interpreted as USH1C-specific prevalence. | Trial-registry search and population-scale genomic analysis | Redfield et al., April 2025, 10.1002/ajmg.c.32142; contemporary therapy review (leith2025currentapproachesfor pages 22-23, redfield2025agenomicanalysis pages 1-4) |
Table: Evidence matrix linking human USH1C/harmonin identity and molecular function to tissue-specific roles, pathogenesis, and translational status. It distinguishes established experimental findings from preclinical therapy results and non-gene-specific epidemiology.
The supplied identity is internally and externally consistent:
A 2023 human-retina study explicitly identified USH1C as the harmonin-encoding human gene and reported ENSG00000006611, 28 exons, a genomic span exceeding 50 kb, and 11 annotated splice transcripts. This independently agrees with the supplied UniProt identity. (nagelwolfrum2023expressionandsubcellular pages 1-2)
The major splice groups are harmonin-a, -b and -c. They share an N-terminal harmonin/HHD module, PDZ1 and PDZ2, plus coiled-coil elements; a and b forms additionally possess PDZ3, while long b isoforms contain further coiled-coil and proline/serine/threonine-rich, actin-binding sequences. Consequently, “harmonin” is not one invariant molecular species: isoforms differ in valency, F-actin association and suitability for particular complexes. (yu2017myosin7and pages 3-3, leith2025currentapproachesfor pages 2-3)
PDZ domains bind short PDZ-binding motifs, commonly at partner C termini. Harmonin’s N-terminal region can cooperate with an adjacent PDZ domain as a supramodule, increasing partner affinity or specificity. Thus, its architecture is optimized for simultaneously clustering several membrane and cytoskeletal proteins rather than catalyzing a chemical reaction. (yu2017myosin7and pages 3-3, whatley2020ushersyndromegenetics pages 12-13)
Harmonin’s central biochemical activity is protein-complex assembly. Principal interactions include:
Accordingly, the most precise functional label is: PDZ-domain scaffold coupling cadherin-based membrane complexes to myosin-associated F-actin networks.
Harmonin-b is concentrated at the upper tip-link density of stereocilia, immediately below the plasma membrane where CDH23 enters the taller stereocilium. There it forms part of a CDH23–harmonin–SANS–MYO7A assembly that anchors mechanically loaded tip links to the actin core. The complex supports hair-bundle development, force transmission and regulation of mechanoelectrical-transduction adaptation. Harmonin is therefore adjacent to, but is not itself, the MET ion channel. (yu2017myosin7and pages 3-3, whatley2020ushersyndromegenetics pages 12-13, leith2025currentapproachesfor pages 2-3)
Functional evidence is stronger than localization alone. Harmonin-deficient or isoform-disrupted mouse hair cells exhibit abnormal bundle morphology and altered MET currents/adaptation. Domain-disruption analyses distinguish PDZ2-dependent bundle development from coiled-coil/PST-dependent effects on displacement sensitivity and adaptation. This supports dual structural and regulatory roles: stabilizing cadherin–actin attachment and setting the mechanical behavior of the transduction apparatus. (leith2025currentapproachesfor pages 2-3)
Harmonin has also been detected at inner-hair-cell ribbon synapses, and studies have proposed effects on presynaptic CaV1.3-channel behavior and exocytosis. These synaptic effects are plausible secondary functions, but the upper-tip-link scaffold is the better-established primary cochlear role. (nagelwolfrum2023expressionandsubcellular pages 16-17)
The 2023 Human Molecular Genetics study substantially refined the retinal annotation. Human retinal RNA sequencing found harmonin-a1 to be the most abundant USH1C transcript. RNA-seq, immunoblotting, immunofluorescence and immunoelectron microscopy placed harmonin in both retinal neurons and Müller glia, including:
These findings suggest several complementary functions: organization of photoreceptor outer-segment membrane proteins, stabilization of Müller-glia–photoreceptor adhesion, and maintenance of ciliary/outer-retinal architecture. The study’s evidence for rhodopsin association supports a direct role in rod outer segments. However, whether harmonin controls rhodopsin trafficking, retention or signaling has not yet been resolved mechanistically. (nagelwolfrum2023expressionandsubcellular pages 8-11)
USH1 proteins also localize to actin-rich photoreceptor calyceal processes in humans and other non-rodent vertebrates. These structures likely mechanically stabilize the outer segment. Their near absence in mice helps explain why many mouse USH1 models fail to reproduce severe human retinal degeneration, an important expert caution for therapeutic studies. (nagelwolfrum2023expressionandsubcellular pages 16-17, dinculescu2021retinalgenetherapy pages 4-6)
In absorptive epithelia, harmonin participates in an analogous intermicrovillar adhesion system. It binds CDHR2/CDHR5 cytoplasmic tails and assembles with MYO7B and ANKS4B, coupling cadherin adhesion complexes to actin bundles. Disrupting this tripartite assembly disorganizes apical microvilli. This reinforces a general organizing principle: harmonin adapts extracellular cadherin adhesion to intracellular actomyosin architecture in specialized actin-rich projections. (yu2017myosin7and pages 3-3, dinculescu2021retinalgenetherapy pages 4-6)
USH1C does not belong to a conventional soluble signaling cascade with a defined enzymatic substrate. Its relevant pathways are spatially organized macromolecular systems:
Biallelic disruptive variants reduce harmonin abundance, alter isoform composition or abolish critical binding surfaces. The immediate molecular consequence is failure to assemble stable cadherin–myosin–actin complexes. In hair cells this disrupts stereociliary development and MET, producing congenital severe-to-profound sensorineural deafness and vestibular areflexia. In the retina, progressive disease likely reflects combined defects in photoreceptors, Müller-glial support, outer-limiting-membrane adhesion and ciliary/outer-segment architecture. (nagelwolfrum2023expressionandsubcellular pages 8-11, nagelwolfrum2023expressionandsubcellular pages 1-2, dinculescu2021retinalgenetherapy pages 4-6)
The recurrent Acadian c.216G>A allele creates an aberrant splice site, leading to frameshifted transcript/protein production. It is especially important translationally because splice-switching ASOs can target the causal RNA-processing defect. By contrast, nonsense or frameshift alleles may require gene replacement, editing or mutation-specific read-through strategies. (cuzzuol2024ushersyndromegenetic pages 5-6, toms2020ushersyndromeclinical pages 8-10)
Human disease progression can be spatially uneven. In the 2023 retinal study, a 35-year-old compound-heterozygous patient with p.R31 and p.Arg80Profs69 had peripheral degeneration, bone spicules, progressive inner-/outer-segment loss and severely reduced or absent full-field ERGs, yet retained foveal structure, 20/25 visual acuity and normal color perception. This single-patient observation is informative but should not be generalized as a natural-history estimate. (nagelwolfrum2023expressionandsubcellular pages 8-11)
The most consequential recent functional advance was the 2023 human-retina study, published in Human Molecular Genetics 32:431–449 (online 23 August 2022; issue publication 2023), DOI 10.1093/hmg/ddac211. It identified harmonin-a1 as the dominant retinal transcript, mapped previously underappreciated Müller-glial and photoreceptor compartments, and showed that harmonin-a1 delivery could reverse a primary-cilium phenotype in patient-derived fibroblasts. These findings nominate harmonin-a1 and multiple retinal cell types for replacement strategies, while cautioning against assuming that photoreceptors alone are the therapeutic target. (nagelwolfrum2023expressionandsubcellular pages 1-2)
For c.216G>A, systemic, amniotic and local inner-ear ASO delivery corrected cryptic splicing and improved auditory/vestibular phenotypes in knock-in mice. A 2024 review reports that P3–P5 dosing restored hearing and vestibular function toward wild-type levels, whereas P10 administration produced only partial auditory rescue despite strong vestibular rescue. Direct round-window ASO-29 delivery at P1 restored correctly spliced transcript toward wild-type abundance and improved hearing thresholds and bundle morphology. Exact effect sizes were not available in the retrieved passages, so “complete rescue” should not be inferred across frequencies or ages. (cuzzuol2024ushersyndromegenetic pages 5-6, leith2025currentapproachesfor pages 21-22, whatley2020ushersyndromegenetics pages 15-16)
The consistent expert interpretation is that timing is a major determinant of efficacy. Rescue before advanced hair-bundle degeneration is much greater than delayed treatment. Mouse postnatal timing also does not map directly onto human cochlear development, much of which occurs prenatally. (cuzzuol2024ushersyndromegenetic pages 5-6, whatley2020ushersyndromegenetics pages 15-16)
Neonatal round-window delivery using AAV2/Anc80L65 produced low-frequency auditory rescue in c.216G>A mice, but the evidence retrieved does not support uniform restoration across the audiometric range or established efficacy in adults. Zinc-finger-nuclease/HDR experiments targeting p.R31X restored harmonin expression in cell-based or preclinical systems; this is proof of molecular correctability, not a demonstrated human therapy. (cuzzuol2024ushersyndromegenetic pages 5-6, toms2020ushersyndromeclinical pages 8-10, leith2025currentapproachesfor pages 19-21)
A harmonin-deficient, humanized USH1C pig reproduces hearing, vestibular and visual abnormalities more faithfully than mice, and ocular AAV delivery has shown indications of in-vivo therapeutic efficacy. Nevertheless, robust dose-ranging, durability, cell-type targeting and safety data are still needed before interpreting this as clinical readiness. (dinculescu2021retinalgenetherapy pages 4-6)
No USH1C-specific interventional clinical trial was identified in the searched registry evidence. The retrieved trial NCT05085964 concerns QR-421a/ultevursen for USH2A, not USH1C, and must not be attributed to harmonin. Current real-world management therefore remains supportive: early genetic diagnosis, hearing aids where useful, cochlear implantation for severe/profound hearing loss, vestibular support and retinal surveillance/low-vision care. USH1C-directed ASO, replacement and editing remain preclinical. (toms2020ushersyndromeclinical pages 8-10, leith2025currentapproachesfor pages 22-23, leith2025currentapproachesfor pages 19-21)
Recent population-scale estimates place all molecular forms of Usher syndrome combined at approximately 1 in 29,000, corresponding to an estimated 30,405 affected individuals in the United States and 721,769 worldwide; approximately 324 US births and 12,090 births worldwide per year were estimated. About 1% of controls carried a pathogenic variant in an Usher gene. These 2025 genomic estimates are not specific to USH1C and should not be used as the prevalence of harmonin deficiency. (redfield2025agenomicanalysis pages 1-4)
A 2024 clinical review cited Usher syndrome at roughly 1 in 6,000 within deaf populations, again representing all genetic subtypes rather than USH1C alone. Available evidence does not provide a reliable contemporary global prevalence for USH1C specifically. (cuzzuol2024ushersyndromegenetic pages 5-6)
Important uncertainties are:
Human USH1C/Q9Y6N9 harmonin is best annotated as a multivalent PDZ scaffold and actin-coupling adaptor. Its defining function is to assemble cadherin, SANS/ANKS4B and myosin-VII proteins into mechanically robust membrane–cytoskeleton junctions. This role is most firmly established at the hair-cell upper tip-link density, extends to retinal photoreceptor/Müller-glial architecture, and is reused in intestinal brush-border microvilli. The 2023 human-retina work materially expanded the accepted cellular map and identified harmonin-a1 as the leading retinal replacement isoform. ASO correction of c.216G>A and AAV/editing studies provide strong preclinical proof of concept, but mutation specificity, developmental timing, delivery and incomplete animal modeling remain substantial barriers; no USH1C-targeted interventional clinical trial was identified.
References
(yu2017myosin7and pages 3-3): I-Mei Yu, Vicente J. Planelles-Herrero, Yannick Sourigues, Dihia Moussaoui, Helena Sirkia, Carlos Kikuti, David Stroebel, Margaret A. Titus, and Anne Houdusse. Myosin 7 and its adaptors link cadherins to actin. Nature Communications, Jun 2017. URL: https://doi.org/10.1038/ncomms15864, doi:10.1038/ncomms15864. This article has 79 citations and is from a highest quality peer-reviewed journal.
(nagelwolfrum2023expressionandsubcellular pages 1-2): Kerstin Nagel-Wolfrum, Benjamin R Fadl, Mirjana M Becker, Kirsten A Wunderlich, Jessica Schäfer, Daniel Sturm, Jacques Fritze, Burcu Gür, Lew Kaplan, Tommaso Andreani, Tobias Goldmann, Matthew Brooks, Margaret R Starostik, Anagha Lokhande, Melissa Apel, Karl R Fath, Katarina Stingl, Susanne Kohl, Margaret M DeAngelis, Ursula Schlötzer-Schrehardt, Ivana K Kim, Leah A Owen, Jan M Vetter, Norbert Pfeiffer, Miguel A Andrade-Navarro, Antje Grosche, Anand Swaroop, and Uwe Wolfrum. Expression and subcellular localization of ush1c/harmonin in human retina provides insights into pathomechanisms and therapy. Text, Jan 2023. URL: https://doi.org/10.25358/openscience-9073, doi:10.25358/openscience-9073. This article has 22 citations and is from a peer-reviewed journal.
(leith2025currentapproachesfor pages 2-3): Fiona K. Leith, Joey Lye, Derek S. Delaney, Samuel McLenachan, Fred K. Chen, Marcus D. Atlas, and Elaine Y. M. Wong. Current approaches for usher syndrome disease models and developing therapies. Frontiers in Cell and Developmental Biology, Jun 2025. URL: https://doi.org/10.3389/fcell.2025.1547523, doi:10.3389/fcell.2025.1547523. This article has 6 citations.
(whatley2020ushersyndromegenetics pages 12-13): Meg Whatley, Abbie Francis, Zi Ying Ng, Xin Ee Khoh, Marcus D. Atlas, Rodney J. Dilley, and Elaine Y. M. Wong. Usher syndrome: genetics and molecular links of hearing loss and directions for therapy. Frontiers in Genetics, Oct 2020. URL: https://doi.org/10.3389/fgene.2020.565216, doi:10.3389/fgene.2020.565216. This article has 69 citations and is from a peer-reviewed journal.
(dinculescu2021retinalgenetherapy pages 4-6): Astra Dinculescu, Brian A. Link, and David A. Saperstein. Retinal gene therapy for usher syndrome: current developments, challenges, and perspectives. International Ophthalmology Clinics, 61:109-124, Sep 2021. URL: https://doi.org/10.1097/iio.0000000000000378, doi:10.1097/iio.0000000000000378. This article has 21 citations and is from a peer-reviewed journal.
(reiners2005scaffoldproteinharmonin pages 1-2): Jan Reiners, Erwin van Wijk, Tina Märker, Ulrike Zimmermann, Karin Jürgens, Heleen te Brinke, Nora Overlack, Ronald Roepman, Marlies Knipper, Hannie Kremer, and Uwe Wolfrum. Scaffold protein harmonin (ush1c) provides molecular links between usher syndrome type 1 and type 2. Human molecular genetics, 14 24:3933-43, Dec 2005. URL: https://doi.org/10.1093/hmg/ddi417, doi:10.1093/hmg/ddi417. This article has 221 citations and is from a domain leading peer-reviewed journal.
(nagelwolfrum2023expressionandsubcellular pages 8-11): Kerstin Nagel-Wolfrum, Benjamin R Fadl, Mirjana M Becker, Kirsten A Wunderlich, Jessica Schäfer, Daniel Sturm, Jacques Fritze, Burcu Gür, Lew Kaplan, Tommaso Andreani, Tobias Goldmann, Matthew Brooks, Margaret R Starostik, Anagha Lokhande, Melissa Apel, Karl R Fath, Katarina Stingl, Susanne Kohl, Margaret M DeAngelis, Ursula Schlötzer-Schrehardt, Ivana K Kim, Leah A Owen, Jan M Vetter, Norbert Pfeiffer, Miguel A Andrade-Navarro, Antje Grosche, Anand Swaroop, and Uwe Wolfrum. Expression and subcellular localization of ush1c/harmonin in human retina provides insights into pathomechanisms and therapy. Text, Jan 2023. URL: https://doi.org/10.25358/openscience-9073, doi:10.25358/openscience-9073. This article has 22 citations and is from a peer-reviewed journal.
(cuzzuol2024ushersyndromegenetic pages 5-6): Beatriz Rocha Cuzzuol, Jonathan Santos Apolonio, Ronaldo Teixeira da Silva Júnior, Lorena Sousa de Carvalho, Luana Kauany de Sá Santos, Luciano Hasimoto Malheiro, Marcel Silva Luz, Mariana Santos Calmon, Henrique de Lima Crivellaro, Fabian Fellipe Bueno Lemos, and Fabrício Freire de Melo. Usher syndrome: genetic diagnosis and current therapeutic approaches. World Journal of Otorhinolaryngology, 11:1-17, Jan 2024. URL: https://doi.org/10.5319/wjo.v11.i1.1, doi:10.5319/wjo.v11.i1.1. This article has 5 citations.
(toms2020ushersyndromeclinical pages 8-10): Maria Toms, Waheeda Pagarkar, and Mariya Moosajee. Usher syndrome: clinical features, molecular genetics and advancing therapeutics. Therapeutic Advances in Ophthalmology, Jan 2020. URL: https://doi.org/10.1177/2515841420952194, doi:10.1177/2515841420952194. This article has 143 citations and is from a peer-reviewed journal.
(leith2025currentapproachesfor pages 21-22): Fiona K. Leith, Joey Lye, Derek S. Delaney, Samuel McLenachan, Fred K. Chen, Marcus D. Atlas, and Elaine Y. M. Wong. Current approaches for usher syndrome disease models and developing therapies. Frontiers in Cell and Developmental Biology, Jun 2025. URL: https://doi.org/10.3389/fcell.2025.1547523, doi:10.3389/fcell.2025.1547523. This article has 6 citations.
(whatley2020ushersyndromegenetics pages 15-16): Meg Whatley, Abbie Francis, Zi Ying Ng, Xin Ee Khoh, Marcus D. Atlas, Rodney J. Dilley, and Elaine Y. M. Wong. Usher syndrome: genetics and molecular links of hearing loss and directions for therapy. Frontiers in Genetics, Oct 2020. URL: https://doi.org/10.3389/fgene.2020.565216, doi:10.3389/fgene.2020.565216. This article has 69 citations and is from a peer-reviewed journal.
(leith2025currentapproachesfor pages 22-23): Fiona K. Leith, Joey Lye, Derek S. Delaney, Samuel McLenachan, Fred K. Chen, Marcus D. Atlas, and Elaine Y. M. Wong. Current approaches for usher syndrome disease models and developing therapies. Frontiers in Cell and Developmental Biology, Jun 2025. URL: https://doi.org/10.3389/fcell.2025.1547523, doi:10.3389/fcell.2025.1547523. This article has 6 citations.
(redfield2025agenomicanalysis pages 1-4): Shelby E. Redfield, Stephanie A. Mauriac, Gwenaëlle S. Géléoc, and A. Eliot Shearer. A genomic analysis of usher syndrome: population-scale prevalence and therapeutic targets. American journal of medical genetics. Part C, Seminars in medical genetics, pages e32142, Apr 2025. URL: https://doi.org/10.1002/ajmg.c.32142, doi:10.1002/ajmg.c.32142. This article has 5 citations.
(nagelwolfrum2023expressionandsubcellular pages 16-17): Kerstin Nagel-Wolfrum, Benjamin R Fadl, Mirjana M Becker, Kirsten A Wunderlich, Jessica Schäfer, Daniel Sturm, Jacques Fritze, Burcu Gür, Lew Kaplan, Tommaso Andreani, Tobias Goldmann, Matthew Brooks, Margaret R Starostik, Anagha Lokhande, Melissa Apel, Karl R Fath, Katarina Stingl, Susanne Kohl, Margaret M DeAngelis, Ursula Schlötzer-Schrehardt, Ivana K Kim, Leah A Owen, Jan M Vetter, Norbert Pfeiffer, Miguel A Andrade-Navarro, Antje Grosche, Anand Swaroop, and Uwe Wolfrum. Expression and subcellular localization of ush1c/harmonin in human retina provides insights into pathomechanisms and therapy. Text, Jan 2023. URL: https://doi.org/10.25358/openscience-9073, doi:10.25358/openscience-9073. This article has 22 citations and is from a peer-reviewed journal.
(leith2025currentapproachesfor pages 19-21): Fiona K. Leith, Joey Lye, Derek S. Delaney, Samuel McLenachan, Fred K. Chen, Marcus D. Atlas, and Elaine Y. M. Wong. Current approaches for usher syndrome disease models and developing therapies. Frontiers in Cell and Developmental Biology, Jun 2025. URL: https://doi.org/10.3389/fcell.2025.1547523, doi:10.3389/fcell.2025.1547523. This article has 6 citations.